Related Experiment Video
Updated: Jul 19, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Hypertension and antihypertensive treatment of diabetic nephropathy
1Department of Internal Medicine, Ruperto Carola University, Heidelberg, Germany. prof.e.ritz@t-online.de
Insights
Managing blood pressure and blocking the renin-angiotensin system (RAS) are crucial for preventing and slowing diabetic nephropathy progression. Early intervention, especially in pre-diabetic stages, significantly reduces kidney damage in diabetes.
Area of Science:
- Nephrology
- Endocrinology
- Cardiovascular Medicine
Background:
- Diabetic nephropathy is a leading cause of renal failure, with hypertension as a major risk factor.
- Genetic predisposition to hypertension increases the risk of both diabetes and diabetic nephropathy.
- Renin-angiotensin system (RAS) blockade offers benefits beyond blood pressure reduction in diabetes.
Purpose of the Study:
- To review the impact of blood pressure management and RAS blockade on diabetic nephropathy.
- To highlight the importance of early intervention and proteinuria reduction.
Main Methods:
- Review of current guidelines and experimental studies on hypertension and diabetic nephropathy.
- Analysis of the role of blood pressure targets and RAS blockade in disease progression.
Main Results:
- Elevated systolic blood pressure above 110 mmHg progressively increases diabetic nephropathy risk.
- Blood pressure lowering and RAS blockade delay or prevent microalbuminuria and slow disease progression.
- Proteinuria is a key treatment target, aiming for reduction below 1 g/24 h.
Conclusions:
- Controlling blood pressure and blocking the RAS are essential for managing diabetic nephropathy.
- Early RAS blockade in pre-diabetic stages can ameliorate subsequent kidney damage.
- Integrated management of blood pressure and proteinuria is vital for preserving renal function in diabetic patients.
Abstract:
We are currently confronted with an epidemic of renal failure caused by diabetic nephropathy. It has become apparent that blood pressure is a major determinant of the risk of developing diabetic nephropathy; individuals with a genetic predisposition to hypertension are at increased risk of developing diabetes and diabetic nephropathy. Antihypertensive medication has an impact on development of diabetes; beyond blood-pressure lowering, the risk of diabetes is further reduced by blockade of the renin-angiotensin system (RAS). In experimental studies, blockade of the RAS in the pre-diabetic stage ameliorates the severity of subsequent diabetic nephropathy. Guidelines recommend a target blood pressure of 130/80 mmHg for diabetic patients without proteinuria and some guidelines recommend a target of less than 125/175 mmHg for diabetic patients with proteinuria. Above a systolic blood pressure of approximately 110 mmHg, the risk of progression of diabetic nephropathy increases progressively with increasing blood pressure. Blood-pressure lowering and blockade of the RAS delays or prevents onset of microalbuminuria, slows worsening of microalbuminuria and attenuates progression of diabetic nephropathy, even in advanced stages. In addition to blood pressure, proteinuria is a treatment target and should be reduced to below 1 g/24 h.
Related Concept Videos
Diabetic Nephropathy
Antihypertensive Drugs: Action of Diuretics
Hypertension IV: Drug Therapy and Lifestyle Modifications
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hypertension V: Nursing Management
Diabetic Retinopathy